Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Regina Juanbeltz, Silvia Goñi Esarte, Juan Isidro Úriz-Otano, Ana Martínez Echeverría, Inmaculada Elizalde, José Manuel Zozaya, Jesús Castilla & Ramón San Miguel. (2017) Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgraduate Medicine 129:4, pages 476-483.
Read now
Read now
Vicente Gimeno-Ballester, Miguel Ángel Simón, Cristina Trigo, Javier Mar & Ramón San Miguel. (2016) Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. Expert Review of Gastroenterology & Hepatology 10:11, pages 1289-1303.
Read now
Read now
Vincent Soriano, Pablo Labarga, Carmen de Mendoza, José V Fernández-Montero, Isabella Esposito, Laura Benítez-Gutiérrez, José M Peña & Pablo Barreiro. (2016) New hepatitis C therapies for special patient populations. Expert Opinion on Pharmacotherapy 17:2, pages 217-229.
Read now
Read now
Isabella Esposito, Pablo Labarga, Pablo Barreiro, José V Fernandez-Montero, Carmen de Mendoza, Laura Benítez-Gutiérrez, José M Peña & Vicente Soriano. (2015) Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects. Expert Opinion on Drug Safety 14:9, pages 1421-1434.
Read now
Read now
Vincent Soriano, Pablo Labarga, Pablo Barreiro, José V Fernandez-Montero, Carmen de Mendoza, Isabella Esposito, Laura Benítez-Gutiérrez & José M Peña. (2015) Drug interactions with new hepatitis C oral drugs. Expert Opinion on Drug Metabolism & Toxicology 11:3, pages 333-341.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Giuseppina Minei, Filomena Morisco, Francesco Borrelli, Nicola Coppola & Guglielmo Borgia. (2014) Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and Clinical Risk Management 10, pages 493-504.
Read now
Read now
Laure Izquierdo, François Helle, Catherine François, Sandrine Castelain, Gilles Duverlie & Etienne Brochot. (2014) Simeprevir for the treatment of hepatitis C virus infection. Pharmacogenomics and Personalized Medicine 7, pages 241-249.
Read now
Read now
Tetsuo Takehara. (2014) Simeprevir for the treatment of chronic hepatitis C genotype 1 infection. Expert Review of Anti-infective Therapy 12:8, pages 909-917.
Read now
Read now
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo & Guglielmo Borgia. (2014) Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. Expert Review of Anti-infective Therapy 12:7, pages 763-773.
Read now
Read now
Ramón San Miguel, Vicente Gimeno-Ballester & Javier Mar. (2014) Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Review of Pharmacoeconomics & Outcomes Research 14:3, pages 387-402.
Read now
Read now
Articles from other publishers (25)
Yuan Wu, Pingyun Wu, Ruolan Wu, Huilong Li, Yao Duan, Chaoni Cai, Zixin Liu, Pengfei She & Di Zhang. (2023) Simeprevir restores the anti-Staphylococcus activity of polymyxins. AMB Express 13:1.
Crossref
Crossref
Taťána Majerová & Jan Konvalinka. (2022) Viral proteases as therapeutic targets. Molecular Aspects of Medicine 88, pages 101159.
Crossref
Crossref
Shams Tabrez, Fazlur Rahman, Rahat Ali, Fida Muhammad, Bader Mohammed Alshehri, Mohammed A. Alaidarous, Saeed Banawas, Abdul Aziz Bin Dukhyil & Abdur Rub. (2021)
Repurposing of
FDA
‐approved drugs as inhibitors of sterol C‐24 methyltransferase of
Leishmania donovani
to fight against leishmaniasis
. Drug Development Research 82:8, pages 1154-1161.
Crossref
Crossref
Jeremy D. Baker, Rikki L. Uhrich, Gerald C. Kraemer, Jason E. Love & Brian C. Kraemer. (2021) A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease. PLOS ONE 16:2, pages e0245962.
Crossref
Crossref
Joy Y. Feng & Adrian S. Ray. 2021. Viral Replication Enzymes and their Inhibitors Part A. Viral Replication Enzymes and their Inhibitors Part A
63
82
.
Sindhuri Upadrasta & Vikas Yadav. 2021. Translational Biotechnology. Translational Biotechnology
347
369
.
Rasha M. Ahmed, Marwa A. A. Fayed, Mohammed F. El-Behairy & Inas A. Abdallah. (2020)
Identification, isolation, structural characterization,
in silico
toxicity prediction and
in vitro
cytotoxicity assay of simeprevir acidic and oxidative degradation products
. RSC Advances 10:70, pages 42816-42826.
Crossref
Crossref
Chih-Wei Lin, Sandeep Dutta, Armen Asatryan, Yi-Lin Chiu, Haoyu Wang, Jack CliftonIIII, Andrew Campbell & Wei Liu. (2017) Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study. Journal of Pharmaceutical Sciences 106:2, pages 645-651.
Crossref
Crossref
Tomokazu Kawaoka, Michio Imamura, Kei Morio, Yuki Nakamura, Masataka Tsuge, C. Nelson Hayes, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Kouhei Ishiyama, Kentaro Ide, Hirotaka Tashiro, Hideki Ohdan & Kazuaki Chayama. (2016) Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. Hepatology Research 46:7, pages 707-712.
Crossref
Crossref
Amel Meguellati, Abdelhakim Ahmed-Belkacem, Alessandra Nurisso, Wei Yi, Rozenn Brillet, Nawel Berqouch, Laura Chavoutier, Antoine Fortuné, Jean-Michel Pawlotsky, Ahcène Boumendjel & Marine Peuchmaur. (2016) New pseudodimeric aurones as palm pocket inhibitors of Hepatitis C virus RNA-dependent RNA polymerase. European Journal of Medicinal Chemistry 115, pages 217-229.
Crossref
Crossref
D. Banerjee & K. R. Reddy. (2016) Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Alimentary Pharmacology & Therapeutics 43:6, pages 674-696.
Crossref
Crossref
AbdullahS Alghamdi, Mohammed Alghamdi, FaisalM Sanai, Hamdan Alghamdi, Faisal Aba-Alkhail, Khalid Alswat, Mohammed Babatin, Adel Alqutub, Ibrahim Altraif & Faleh Alfaleh. (2016) Saslt guidelines: Update in treatment of Hepatitis C virus infection. Saudi Journal of Gastroenterology 22:8, pages 25.
Crossref
Crossref
Tomokazu Kawaoka, Shoichi Takahashi, Yoshiiku Kawakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hideyuki Hyogo, Hiroshi Aikata, Kohei Ishiyama, Hirotaka Tashiro, Hideki Ohdan, Junko Tanaka & Kazuaki Chayama. (2015) Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. Hepatology Research 45:11, pages 1047-1054.
Crossref
Crossref
Cory L. Simpson, Drew McCausland & Emily Y. Chu. (2015) Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C. Journal of Cutaneous Pathology 42:10, pages 769-773.
Crossref
Crossref
Paul Y. Kwo & Maaz B. Badshah. (2015) New hepatitis C virus therapies. Current Opinion in Organ Transplantation 20:3, pages 235-241.
Crossref
Crossref
Borja Mora-Peris, Laura Else, David Goldmeier, Alison Mears, Rosy Weston, Graham Cooke, Saye Khoo, David Back & Alan Winston. (2015) A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. Journal of Antimicrobial Chemotherapy 70:6, pages 1812-1815.
Crossref
Crossref
Michael S. Forman & Alexandra Valsamakis. 2015.
Manual of
Clinical Microbiology
.
Manual of
Clinical Microbiology
1599
1616
.
T. Kawaoka, M. Imamura, H. Kan, H. Fujino, T. Fukuhara, T. Kobayashi, Y. Honda, N. Naeshiro, A. Hiramatsu, M. Tsuge, C.N. Hayes, Y. Kawakami, H. Aikata, H. Ochi, K. Ishiyama, H. Tashiro, H. Ohdan & K. Chayama. (2015) Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report. Transplantation Proceedings 47:3, pages 809-814.
Crossref
Crossref
Wendy Cheng, Saroj Nazareth & James Patrick Flexman. (2015) Statewide hepatitis C model of care for rural and remote regions. Journal of Gastroenterology and Hepatology 30, pages 1-5.
Crossref
Crossref
Peter Kovacic & Ratnasamy Somanathan. 2015. Oxidative Stress: Diagnostics, Prevention, and Therapy Volume 2. Oxidative Stress: Diagnostics, Prevention, and Therapy Volume 2
221
235
.
Benjamin Maasoumy, Bela Hunyady, Vincenza Calvaruso, Mihály Makara, Johannes Vermehren, Attila Haragh, Simone Susser, Birgit Bremer, Gavin Cloherty, Michael P. Manns, Antonio Craxì, Heiner Wedemeyer & Christoph Sarrazin. (2014) Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. PLoS ONE 9:11, pages e110857.
Crossref
Crossref
Dalibor Novotny, Lucie Roubalova, Kvetoslava Aiglova, Jana Bednarikova & Margita Bartkova. (2014) IL28B genotyping and treatment of HCV infected subjects. Asian Biomedicine 8:4, pages 445-452.
Crossref
Crossref
Mitchell L. Shiffman, April G. Long, Amy James & Phillip Alexander. (2014) My Treatment Approach to Chronic Hepatitis C Virus. Mayo Clinic Proceedings 89:7, pages 934-942.
Crossref
Crossref
Blaire E. Burman, Paul Y. Kwo & Kris V. Kowdley. (2014) Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. Hepatology International 8:3, pages 352-364.
Crossref
Crossref
Erik De Clercq. (2014) Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochemical Pharmacology 89:4, pages 441-452.
Crossref
Crossref